Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

30 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Termination rates and histological reclassification of active surveillance patients with low- and early intermediate-risk prostate cancer: results of the PREFERE trial.
Albers P, Wiegel T, Schmidberger H, Bussar-Maatz R, Härter M, Kristiansen G, Martus P, Meisner C, Wellek S, Grozinger K, Renner P, Burmester M, Schneider F, Stöckle M. Albers P, et al. Among authors: bussar maatz r. World J Urol. 2021 Jan;39(1):65-72. doi: 10.1007/s00345-020-03154-7. Epub 2020 Mar 18. World J Urol. 2021. PMID: 32189088 Free PMC article. Clinical Trial.
[The importance of pathology in the German prostate cancer study PREFERE].
Kristiansen G, Stöckle M, Albers P, Schmidberger H, Martus P, Wellek S, Härter M, Bussar-Maatz R, Wiegel T. Kristiansen G, et al. Among authors: bussar maatz r. Pathologe. 2013 Sep;34(5):449-62. doi: 10.1007/s00292-013-1788-8. Pathologe. 2013. PMID: 23963533 Review. German.
[PREFERE - Study on the rise].
Ohlmann CH, Stöckle M, Albers P, Schmidberger H, Härter M, Kristiansen G, Martus P, Wellek S, Bussar-Maatz R, Wiegel T. Ohlmann CH, et al. Among authors: bussar maatz r. Urologe A. 2016 Mar;55(3):313-7. doi: 10.1007/s00120-016-0047-z. Urologe A. 2016. PMID: 26908120 Clinical Trial. German.
Results of a randomized trial of treatment modalities in patients with low or early-intermediate risk prostate cancer (PREFERE trial).
Wiegel T, Albers P, Bartkowiak D, Bussar-Maatz R, Härter M, Kristiansen G, Martus P, Wellek S, Schmidberger H, Grozinger K, Renner P, Schneider F, Burmester M, Stöckle M. Wiegel T, et al. Among authors: bussar maatz r. J Cancer Res Clin Oncol. 2021 Jan;147(1):235-242. doi: 10.1007/s00432-020-03327-2. Epub 2020 Sep 4. J Cancer Res Clin Oncol. 2021. PMID: 32886212 Free PMC article. Clinical Trial.
Reply to Andreas Boehle, Frank Kahmann, Thomas Oliver Henkel, Joerg Zimmermann and Stefan Machten's to the Letter to the editor Re: results of a randomized trial of treatment modalities in patients with low or early-intermediate risk prostate cancer (PREFERE trial).
Wiegel T, Albers P, Bartkowiak D, Bussar-Maatz R, Härter M, Kristiansen G, Martus P, Wellek S, Schmidberger H, Grozinger K, Renner P, Schneider F, Burmester M, Stöckle M. Wiegel T, et al. Among authors: bussar maatz r. J Cancer Res Clin Oncol. 2021 Apr;147(4):1273-1274. doi: 10.1007/s00432-021-03549-y. J Cancer Res Clin Oncol. 2021. PMID: 33625578 Free PMC article. No abstract available.
[Localised prostate cancer: the PREFERE trial].
Stöckle M, Bussar-Maatz R. Stöckle M, et al. Among authors: bussar maatz r. Z Evid Fortbild Qual Gesundhwes. 2012;106(5):333-5; discussion 335. doi: 10.1016/j.zefq.2012.05.004. Epub 2012 Jun 18. Z Evid Fortbild Qual Gesundhwes. 2012. PMID: 22818151 Clinical Trial. German.
Correction to: Results of a randomized trial of treatment modalities in patients with low or early-intermediate risk prostate cancer (PREFERE trial).
Wiegel T, Albers P, Bartkowiak D, Bussar-Maatz R, Härter M, Kristiansen G, Martus P, Wellek S, Schmidberger H, Grozinger K, Renner P, Schneider F, Burmester M, Stöckle M. Wiegel T, et al. Among authors: bussar maatz r. J Cancer Res Clin Oncol. 2021 Jan;147(1):243-244. doi: 10.1007/s00432-020-03497-z. J Cancer Res Clin Oncol. 2021. PMID: 33346877 Free PMC article. No abstract available.
30 results